tradingkey.logo
搜尋

Precigen Inc

PGEN
添加自選
6.270USD
+0.330+5.56%
收盤 07-31 16:00美東報價延遲15分鐘
2.24B總市值
虧損本益比TTM

關於 Precigen Inc 公司

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc簡介

公司代碼PGEN
公司名稱Precigen Inc
上市日期Aug 08, 2013
CEOSabzevari (Helen)
員工數量143
證券類型Ordinary Share
年結日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20876
電話13015569900
網址https://precigen.com/
公司代碼PGEN
上市日期Aug 08, 2013
CEOSabzevari (Helen)

Precigen Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.77M
--
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
202.10K
+45.27%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
139.37K
+23.12%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.77M
--
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%

常見問題

Precigen Inc的前五大股東是誰?

Precigen Inc的前五大股東如下:Dr. Helen Sabzevari, Ph.D.

有多少機構持有Precigen Inc(PGEN)的股份?

截至2026Q1,共有355家機構持有Precigen Inc的股份,合計持有的股份價值約為270.08M,占公司總股份的75.82% 。與2025Q4相比,機構持股有所增加,增幅為16216262.00。

哪個業務部門對Precigen Inc的收入貢獻最大?

在2026Q1,Product業務部門對Precigen Inc的收入貢獻最大,創收3.98M,占總收入的41.05% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有